F
Fountain Therapeutics
Biotech & Life Sciences · South San Francisco, United States · Founded 2018
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases MoreLess
Fountain Therapeutics operates at the intersection of biotechnology and artificial intelligence, focusing on the development of therapeutics that target cellular resilience to combat chronic degenerative diseases. The company leverages its proprietary AI-driven technology, which incorporates advanced machine learning and computer vision, to model and modify cellular health. Fountain's primary clients include healthcare providers, pharmaceutical companies, and research institutions. Operating within the biotech and healthcare markets, Fountain employs a business model centered around the research and development of novel therapeutics, which it monetizes through partnerships, licensing agreements, and direct sales of its therapeutic solutions. The company aims to address the underlying causes of aging-related diseases, offering innovative treatments that improve both the quality and length of life.
Keywords: AI-driven therapeutics, cellular resilience, chronic diseases, degenerative diseases, biotechnology, machine learning, computer vision, healthcare, pharmaceutical, research institutions.
Company overview
Fountain Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- South San Francisco, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 56.4
Valuation & funding
Fountain Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2021 | $15M | $60M | Eli Lilly · R42 Group · Khosla Ventures · Nan Fung Life Sciences Real Estate | — |
| SERIES A✓Equity / VC | May 2020 | $6M | $24M | Khosla Ventures · Nan Fung Life Sciences Real Estate | ↗ |
| SERIES A✓Equity / VC | May 2018 | $5M | $20M | Pivotal Life Sciences · Nan Fung Life Sciences Real Estate | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 4 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 15 |
| 2022 | 18 |
| 2021 | 15 |
| 2020 | 11 |
Growth signals
Fountain Therapeutics website traffic
Latest recorded traffic for Fountain Therapeutics is 840 monthly website visits, down 14.3% over the last three months. Fountain Therapeutics's team grew 0% over the past year.
Comparisons
Fountain Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Fountain Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Fountain Therapeutics has talent and traffic
team presence
In the news
Latest news about Fountain Therapeutics
Recent press, funding announcements, and product moves mentioning Fountain Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Fountain Therapeutics
An AI-synthesized read of the highest-engagement posts about Fountain Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fountain Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.